Seattle Genetics is a firm that was found in the year 1998 by Dr. Clay Siegall together with another co-founder. He was elected the company’s CEO and has been serving also as the chairman of the board and the president of the firm as well. The firm has developed a strong reputation for cancer drugs such as the ADCETRI, one of the drugs has received approval from the United States Food and Drug Administration since 2011.
Dr. Siegall is an active contributor to the success of the company’s financial growth. He has been guiding the company in acquiring funds from private and governmental companies and has managed to secure an amount more than $675 million. His career initially started at the Bristol-Myers Squibb Pharmaceutical Research Institute and earlier working with the National Cancer Institute, National Institute of Health. He forms part of the board of the Alder Biopharmaceutical company. His achievements in career include fifteen patents and have also published over seventy publications. He is also holding a Ph.D. IN Genetics and a Bachelors Degree in Zoology.
From the first instance of the Bothell’s Cascade Business Park won’t give the picture of edgy science. However, within the lobby, you find the triangular sculpture that is designed in the form of the human antibody. This is simply the symbol of the content making up the fiber of the company’s task since the year of its founding. The firm has majored into the study of the human antibody, manipulating them and incorporating them into the drug design for treatment. The cancer therapy designed with an antibody that attacks the cancer cell from the interiors, delivering a toxic payload to destroy the cell.
This therapy strategy has projected the Seattle Genetics into the position of the mighty. Seattle Genetics controls a market value of $10 billion and has a total number of 900 employees. It is in the rank as the top in the biotech field in the city of Washington. The company’s ambition is to rise from just a biotech company into a big pharma and to reach its target, it has invested in diverse research and marketing and plans to increase its workforce by bringing in 200 more employees. The company’s new drug discovery, the ADCETRIS, is a therapy that cures the cancer of the lymph known as Hodgkin lymphoma that poses a risk of also spread to other parts of the body. Research on the same drug continues and will be released to the market once approved positive.
Born on the 2nd of September 1969, Eric Lefkofsky is an entrepreneur from the United States of America. He spent his childhood in Michigan and attended Southfield-Lathrup High school and later graduated from University of Michigan in 1991 with honors. He then continued with law studies at the same university and graduated in 1993.
Brief Entrepreneurial History
Eric began his entrepreneurial life as a carpet seller in University of Michigan. It was after his graduation from law school that Eric Lefkofsky and his college friend started up their first company. This made the debut of the founding of his many businesses Eric Lefkofsky is one of the co-founders and also the chief executive officer (CEO) of Tempus. In addition to this, he also happens to among the co-founders of Groupon, Echo Global Logistics and also Lightbank, which a Chicago-based capital firm.
Tempus is a technology-based company which has built an OS (Operating system) to help battle cancer. He quit his chief executive officer role at Groupon so that he could work on Tempus. This is a health technology startup that is building infrastructure to help bring up to date cancer treatment. The role of the company is to assist doctors and other healthcare specialists to come up with real-time, data-driven and individualized patient treatment and management decisions after the analysis of the given patient’s genetic code.Eric Lefkofsky partnered with Brad Keywell in initiating Tempus. Eric and Brad have a lot in common. There are so many businesses they run together. They always spend quality time identifying solutions for problems they might be experiencing. Their corporate duty in determining viable remedies for problems affecting them has taken them a long way in impacting societies.
Eric’s Philanthropic Activities
Lefkofsky Family Foundation is a private philanthropic foundation which was established by Eric Lefkofsky and his wife in 2006. The foundation was created so as to aid in the advancement of high-impact projects which usually enhance the lives of the people in the communities that they serve. It is through this foundation that Lefkofsky and his wife have been able to give regular donations to cancer research centers and causes. At Lurie Children’s Hospital in Chicago, Lefkofsky is also a trustee.
One of the outstanding characters that Clay Siegall has shown with remarkable consistence over the years is his commitment and strong conviction towards finding a better alternative treatment for cancer. While drawing inspiration from early personal experience with cancer, Dr. Clay Siegall has used his experience as a company executive, entrepreneur, research scientist and scholar to lead the research and development for innovative and technology-based alternative cancer therapies that are more effective and cause less pain to the patients compared to conventional treatment options.
Such strong commitment and dedication towards his duties as the cofounder and chief executive officer at Seattle Genetics has seen him guide the company towards operational and financial success despite significant challenges. Despite taking significantly long to generate profits, Dr. Siegall had strong faith in the company’s legal and sales teams, which have played critical roles in the company’s ability to finally realize financial success ten years after its initial public offer (IPO). He has also guided the company towards strategic partnerships with several key industry players including Bayer and Pfizer. These partnerships have been crucial in the success of the company’s research efforts towards developing an effective conjugate therapy for treatment of cancer. Clay Siegall believes that strong focus and intense passion for the task at hand is the primary key to success.
Commitment to Cancer Community
Clay Siegall is a remarkable company executive who has dedicated his professional career, education and company resources towards alleviating the pain cancer patients and their families go through. His interest in cancer and related fields began at the University of Maryland where he graduated with a Bachelor of Science in Zoology. He later specialized in genetics for his Doctor of Philosophy degree studies at George Washington University. His scholarly endeavors in the subject has also seen author several papers on the topic while also working for several organizations specializing in cancer research. This is in addition to the 15 patents to his name and over one billion dollars raised towards effective and innovative cancer therapies and drugs development and research. Currently, the company is on the verge on adding over a dozen new targeted treatment drugs to Adcentris, which has already been approved by the FDA.
The Cancer Treatment Centers of America is creating new change and providing their physicians with the latest new technology that is going to create massive change in the world. This amazing new addition is going to make huge changes to the way they work. The Cancer Treatment Centers of America is very well respected because of their new Clinical Pathways that’s going to revolutionize how so many in this business work. In the world of treatments and all the different options available, it can be tough to know what you need and what a patient should get.
As stated on Wikipedia, Clinical Pathways is the right way to help improve what they have been working on over the years. For example, Clinical Pathways works hard every single day to provide physicians with the right answers for patients. In a world where it’s scary and extremely difficult for a patient to find a treatment that best suits their state of health, Clinical Pathways can solve this issue. According to this article, when a cancer patient is at odds and has to weigh out the pros and cons on whether something is worthwhile for their health or not, this unique little tool is gonna help patients and the physicians out in regards to knowing what to go for specifically.
Cancer Treatment Centers of America wanted to create this technology to provide simplicity and safety. Users can actually use this tool to figure out which appropriate treatment options are available alongside how much they cost, the different affects to think about, and the important data you must know in regards to a person’s needs and state of health. There is more to the story than just choosing between two different types of treatment options. The Cancer Treatment Centers of America is here to give hope and spread only the best technology to those who are currently dealing with a stressful cancer at the moment.